From the Guidelines
Jardiance (empagliflozin) is primarily indicated for adults with type 2 diabetes mellitus to improve glycemic control, alongside diet and exercise, as well as for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF), regardless of whether they have diabetes.
Indications for Jardiance (Empagliflozin)
- Improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise 1
- Reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease 1
- Reduce the risk of cardiovascular death and hospitalization for heart failure in adults with HFrEF or HFpEF, regardless of whether they have diabetes 1
- Reduce the risk of sustained decline in estimated glomerular filtration rate, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease 1
Dosage and Administration
- The typical starting dose is 10 mg once daily, taken in the morning, with a maximum dose of 25 mg daily 1
- Empagliflozin works by inhibiting sodium-glucose cotransporter-2 (SGLT2) in the kidneys, which increases urinary glucose excretion and reduces blood glucose levels
Important Considerations
- Patients should be monitored for potential side effects including urinary tract infections, genital mycotic infections, and volume depletion, especially when initiating therapy 1
- Empagliflozin is not recommended for glucose lowering in patients with eGFR <45 mL/min/1.73 m², and is contraindicated in patients on dialysis 1
From the FDA Drug Label
JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.
The indication for Jardiance (empagliflozin) is:
- Type 2 diabetes mellitus: as an adjunct to diet and exercise to improve glycemic control in adults
- Cardiovascular risk reduction: to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease 2
From the Research
Indication for Jardiance (Empagliflozin)
The indication for Jardiance (empagliflozin) is for the treatment of adults with type 2 diabetes (T2D) in the EU, USA, and Japan, among other parts of the world 3, 4, 5, 6.
- Empagliflozin is approved for the treatment of T2D as monotherapy or as a component of combination therapy with other antidiabetic agents with complementary modes of action to improve glycaemic control in patients with T2D 3.
- It is also indicated for the reduction of cardiovascular (CV) death in adults with T2D and CV disease (CVD) 7.
- Empagliflozin has shown cardioprotective and renoprotective properties largely independent of glycaemic control in patients with T2D and established CVD 3, 7.
Benefits of Empagliflozin
The benefits of empagliflozin include:
- Improvement in glycaemic control 3, 4, 5
- Reduction in body weight and blood pressure 3, 4, 5
- Low inherent risk of hypoglycaemia 3, 4, 5
- Cardiovascular protection 4, 7
- Renoprotective properties 7
Usage of Empagliflozin
Empagliflozin can be administered orally, once daily, at doses of 10 mg and 25 mg 4. It is generally well tolerated as monotherapy or as add-on therapy, with a low risk of hypoglycaemia and no increased risk of amputation or bone fractures 3.